摘要
为了探讨替吉奥联合奥沙利铂对转移性三阴乳腺癌患者随机对照研究及对血清P53抗体(serum P53antibody,P53)、第十号染色体同源丢失性磷酸酶-张力蛋白基(phosphatase and tensin homolog deleted from chromosome ten,PTEN)的影响。将90例转移性三阴乳腺癌患者按系统随机化法分为对照组45例和观察组45例。对照组采用奥沙利铂135 mg/m^2+1 000 m L Glu,静脉滴注,每4周1次,行3个疗程的化疗。观察组在对照组的基础上加用替吉奥胶囊40~60 mg/次,2次/d,每4周1次进行治疗,行3个疗程的化疗。比较2组患者的治疗后的临床疗效、血清P53、PTEN及HIF-α水平及毒副作用。结果表明观察组的总有效率及控制率与对照组比较无明显差异(p>0.05),但观察组患者的稳定率(44.44%)明显高于对照组(22.22%)(p<0.05)。2组患者的P53、HIF-α指标与治疗前相比均明显降低(p<0.05),且观察组患者低于对照组(p<0.05);2组患者的PTEN水平与治疗前相比,均明显升高(p<0.05),且观察组高于对照组(p<0.05)。观察组患者不良反应发生率为11.11%与对照组的17.77%相比,无明显差异(p>0.05)。替吉奥联合奥沙利铂治疗转移性三阴乳腺癌疗效肯定,能改善患者血清P53、PTEN及HIF-α水平,且毒副反应小。
To explore S-1 （SOX） joint Oxaliplatin into randomized study in patients with triple-negative breast cancer and the influence of PTEN, p53. Ninety patients with triple-negative breast cancer were divided into control group （n=45） and observation group （n=45） by the method of system randomization. Control group adopted Oxaliplatin into 135 mg/m^2 and 1 000 mL Glu, intravenous drip, once for every 4 weeks, under 3 courses of chemotherapy. On the basis of the control group, the observation group used S-1, capsule 40-60 mg/times, twice a day, every 4 weeks for a treatment, and under 3 courses of chemotherapy. To compare the two groups after treatment in patients with the clinical curative effect, the serum levels of P53, PTEN, HIF-α level and side effects were evaluated. The result showed that the total effective rate and control rates between observation and control group, there＇s no significant difference （o〉0.05）. But the stability factor of observation group patients （44.44%） was significantly higher than control group （22.22%） （,0〈0.05）. Compared with before treatment, two groups of patients with P53, HIF-α index were significantly decreased （p〈0.05）, the patients of observation group is significantly lower than the control group （p〈0.05）. Compared with before treatment, PTEN indexes of two groups patients were significantly increased （p〈0.05）, and patients of observation group were obviously higher than that of control group （p〈0.05）. Compared with 17.77% of observation group, the incidence rate of adverse reactions on control group is 17.77%, there was no significant difference （p〉0.05）. S-1 （SOX）joint Oxaliplatin in the treatment of Triple-negative breast cancer curative was effective, and it can improve the P53, PTEN, HIF-α serum levels of patients, and with little adverse reactionm.
出处
《基因组学与应用生物学》
CAS
CSCD
北大核心
2016年第12期3313-3318,共6页
Genomics and Applied Biology
基金
重庆市卫生局项目S-1联合奥沙利铂对转移性三阴乳腺癌解救治疗的随机对照临床观察及相关疗效预测因子研究(20141018)资助
